10-K: Sharps Technology Inc. Reports Full Year 2023 Results, Outlines Strategic Growth Initiatives

Sharps Technology, Inc., a medical device company focused on safety syringe technology, reported its full year 2023 results, highlighting strategic partnerships and ongoing efforts to commercialize its product lines.

Summary

• Sharps Technology, Inc. is a medical device company specializing in safety syringes, with a focus on commercializing its patented technologies.
• The company incurred net losses of $9,841,638 in 2023 and $4,639,662 in 2022, with an accumulated deficit of $25,149,004 as of December 31, 2023.
• Sharps has not yet generated any revenue from the sale of its products.
• The company is working to amend agreements with Nephron Pharmaceuticals Corporation following an asset purchase agreement in September 2023.
• A cooperative sales and distribution agreement was established with Roncadelle Operations s.r.l. in March 2024, granting exclusive distribution rights in various regions.
• A previous distribution agreement with Nephron Pharmaceuticals Corporation was terminated in March 2024.
• The company is building inventory to support the Roncadelle distribution agreement and anticipates receiving additional orders in 2024.
• Sharps' disposable syringe lines have less than 20 microliters of dead space, compared to competitors' syringes with up to 140 microliters.
• The company is developing prefillable syringe systems with a projected product supply beginning in early 2025.
• Sharps has four issued patents, two pending patent applications in the United States, and four PCT patent applications.
• The company has 57 full-time employees, with 50 based in Hungary.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments such as new partnerships and product development, the lack of revenue and significant losses raise concerns. The company's future success is highly dependent on its ability to commercialize its products and secure additional funding.

Positives

• The company has established a cooperative sales and distribution agreement with Roncadelle Operations s.r.l., expanding its market reach.
• Sharps' syringe technology offers ultra-low waste features, potentially providing a competitive advantage.
• The company is actively working to expand its product portfolio into prefillable syringes.
• Sharps has secured intellectual property protection with four issued patents.

Negatives

• The company has incurred significant net losses of $9.8 million in 2023 and $4.6 million in 2022.
• Sharps has not yet generated any revenue from product sales.
• The company terminated its distribution agreement with Nephron Pharmaceuticals Corporation.
• There are ongoing delays in the commercialization of the Sharps Provensa product line.

Risks

• The company has a limited operating history and may not succeed in commercializing its products.
• Sharps faces significant competition from established medical device companies.
• The company is vulnerable to new technologies that could render its products obsolete.
• Product liability claims could negatively impact the company's financial position.
• Changes in healthcare regulations could affect demand for the company's products.
• The company may not be able to raise capital as needed to develop its products or maintain operations.
• The company's stock price could be subject to extreme volatility.
• The company may face delisting from the Nasdaq Capital Market if it does not maintain listing requirements.

Future Outlook

The company intends to finance its future development and commercialization activities and its working capital needs largely from the sale of equity securities and/or with additional funding from other traditional financing sources. Sharps is working towards the purchase of a manufacturing facility from Nephron in South Carolina and anticipates product supply of prefillable syringes beginning in early 2025.

Management Comments

• Management continues to monitor the situation but has not experienced a significant disruption to its product development efforts.
• Management calculates the effective interest rate (EIR) to consider the potential repayment at redemption date by reference to the face value amount after taking into account the stated 8 % interest rate.

Industry Context

The medical device industry is highly competitive, with numerous companies offering safety syringes. Sharps is attempting to differentiate itself through its ultra-low waste technology and focus on both passive and active safety features. The company's expansion into prefillable syringes aligns with a growing market trend for ready-to-use drug delivery systems.

Comparison to Industry Standards

• Sharps' disposable syringe lines have less than 20 microliters of dead space, which is significantly lower than the 70 microliters Low Dead Space designation and the up to 140 microliters dead space found in competitors' syringes.
• Competitors in the safety syringe market include Retractable Technologies, Inc., Becton Dickinson & Company, Medtronic Minimally Invasive Therapies, Terumo Medical Corp., Smiths Medical, and B Braun, all of which have greater financial resources and established sales networks.
• The company's focus on both passive and active safety features aligns with World Health Organization requirements for syringe distribution programs.

Management Changes

Related Party Transactions

• As of December 31, 2023 and 2022, accounts payable and accrued liabilities include $32,974 and $105,667, respectively, payable to officers, and directors of the Company.

Stakeholder Impact

• Shareholders are impacted by the company's net losses and the potential for stock price volatility.
• Employees are affected by the company's financial performance and future growth prospects.
• Customers and suppliers are impacted by the company's ability to commercialize its products and fulfill orders.
• Creditors are impacted by the company's financial stability and ability to repay debts.

Next Steps

• The company will continue to work with Nephron towards the purchase of the Nephron facility.
• Sharps will focus on building inventory to support the sales and distribution agreement with Roncadelle.
• The company will continue discussions with healthcare companies and distributors for sales of its products.
• Sharps plans to advance its new innovative products in connection with recent collaboration arrangements.

Key Dates

Keywords

safety syringes, medical devices, prefillable syringes, ultra-low waste, distribution agreement, manufacturing facility, intellectual property, healthcare, pharmaceuticals, product commercialization